Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 15/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2009306 | 1.00 | ADRB2 (0.44) | ADRB2ADRB1ADRB3SMN1; SMN2MEN1 | |
| SCHEMBL2009303 | 1.00 | ADRB2 (0.44) | ADRB2ADRB1ADRB3SMN1; SMN2MEN1 | |
| SCHEMBL2012556 | 0.91 | ADRB2 (0.56) | ADRB2ADRB1ADRB3 | |
| SCHEMBL2012558 | 0.91 | ADRB2 (0.56) | ADRB2ADRB1ADRB3 | |
| SCHEMBL2012553 | 0.91 | ADRB2 (0.56) | ADRB2ADRB1ADRB3 | |
| SCHEMBL774598 | 0.85 | ADRB2 (0.57) | ADRB2ADRB1ADRB3MEN1KMT2A | |
| SCHEMBL2006706 | 0.84 | ADRB2 (0.64) | ADRB2ADRB1ADRB3 | |
| SCHEMBL2006704 | 0.84 | ADRB2 (0.64) | ADRB2ADRB1ADRB3 | |
| SCHEMBL2006701 | 0.84 | ADRB2 (0.64) | ADRB2ADRB1ADRB3 | |
| SCHEMBL2795663 | 0.82 | ADRB2 (0.45) | ADRB2ADRB1ADRB3MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964730-B2 | Amino-substituted ethylamino β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090111850-A1 | Amino-Substituted Ethylamino Beta2 Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-04-30 | — | — | US | disclosed |
| EP-1687257-B1 | AMINO-SUBSTITUTED ETHYLAMINO BETA2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE INC (US) | 2009-04-15 | — | — | EP | disclosed |
| US-7399863-B2 | Amino-substituted ethylamino β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1687257-A2 | AMINO-SUBSTITUTED ETHYLAMINO &Bgr;2 ADRENERGIC RECEPTOR AGONISTS | Theravance, Inc. (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050113411-A1 | Amino-substituted ethylamino beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-05-26 | — | — | US | disclosed |
| WO-2005030678-A2 | AMINO-SUBSTITUTED ETHYLAMINO β2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111850-A1 | Amino-Substituted Ethylamino Beta2 Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885ADRB1 2/4885ADRB3 6/4885 |
| US-20050113411-A1 | Amino-substituted ethylamino beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885ADRB1 2/4885ADRB3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.